Eton Pharmaceuticals (NASDAQ:ETON) announced on Monday that it has secured U.S. marketing rights for a new ultra-rare disease product candidate, further cementing its position in the specialized orphan drug market.
The asset, which is already under review by the Food and Drug Administration (FDA), is slated for a potential approval and commercial launch by mid-2026.
The licensed product is positioned to become the first and only generic alternative for a condition so rare it affects fewer than 100 patients across the United States.
While the company is withholding specific product details until regulatory approval is finalized, CEO Sean Brynjelsen noted that the "bolt-on asset" aligns seamlessly with Eton’s existing commercial infrastructure.
The company plans to integrate the new treatment into its Eton Cares patient support program, which provides insurance navigation and financial assistance for high-cost rare disease therapies.
The deal follows a period of aggressive expansion for the Illinois-based pharmaceutical firm.
Eton reported a 129% year-over-year surge in product revenue for the third quarter of 2025, driven by its portfolio of eight commercialized rare disease treatments, including Alkindi Sprinkle and Increlex.
With five other candidates in late-stage development—including the ET-600 desmopressin oral solution, which has a looming FDA action date of Feb. 25, 2026—this latest licensing agreement brings Eton closer to its stated goal of maintaining the industry's largest portfolio of ultra-rare disease products.